Improve product launch success

Insights from Inizio experts: Ashley Stanley, Will Reese, and Chris Savage.

In the next article in our series on how Intelligent Commercialization™ supports health and life science companies across the asset lifecycle, Inizio experts explore how forecasting, signals-based targeting, and AI-enabled launch planning can help reduce risk and improve launch readiness.

Why pharma launches are more challenging than ever

The pharma launch planning landscape has changed significantly in recent years. Complex indications, shorter timescales, fewer resources, lower budgets, and fragmented data are just some of the factors that make launching a new product more challenging and uncertain than ever.

“One of the most common questions from our clients is how can they be confident that their launch plan is going to work,” says Chris Savage, Managing Director of Propensity4, an Inizio Engage company. “And of course, you can never be 100% certain about anything. But because we have teams working across the product lifecycle, we can bring our tools, capabilities, and expertise together as part of our approach to Intelligent Commercialization™, which will significantly increase the chances of a successful launch.”

Inizio’s approach to launch planning involves three stages:

1. Forecasting: What’s likely to happen?

Building bottom-up forecasts

We begin by creating a detailed bottom-up forecast that provides a solid basis for making sound investment decisions – essentially tying every dollar spent to anticipated outcomes.

Taking claims, lab tests, and other fundamental asset data, we identify the overall market, before drilling down to understand who our target HCPs are and how best to engage with them.

Using AI to predict HCP adoption and demand

Once we identify the HCPs and their patients, we use data-driven insights to understand how quickly they are likely to adopt, overlaying operational realities such as competitor impact, market access, and payer needs.

“By marrying customer data, our internal expertise, and Inizio’s AI-driven platforms, we’re able to get right down to the individual HCP and patient level, to understand them in an incredibly detailed way,” says Chris. “We can then roll that up to a district or regional level, tailoring our approach based on the nuances and differences we see.”

From here, Inizio can then start to model demand and likely adoption levels based on multiple factors, such as competitor launch information and adjacent markets with similar competitor landscapes.

“Through this approach we’re able to target not just the HCPs we class as innovators or early adopters, but also those typically seen as late adopters, ensuring they feel more comfortable with the product,” says Chris.

2. Signals-based targeting: Who do you influence and when?

Why traditional pharma launch models no longer work

Once you have a forecast and an understanding of the market, how do you optimally profile, target, and behaviorally activate your customers?

“The challenges companies face now mean the old ways of working are no longer fit for purpose,” explains Will Reese, Chief Innovation Officer at Inizio Evoke. “Broad, static HCP engagement; generic content and equal spend across channels and localized markets; high-cost, field-heavy resourcing; and a reactive approach to finding opportunities, just won’t cut it today, the landscape is too complex.

“The brands that launch most successfully now are the ones using dynamic, data-driven orchestration and investing in specific target profiles through high-ROI channels, delivered with a personalized experience. They embrace AI to plan and continuously optimize an omnichannel approach and use signals-based activation that identifies and engages around the highest-value patient moments.”

Turning healthcare signals into commercial action

These real-world ‘signals’ are everywhere. They relate to the way patients are currently diagnosed or treated as well as existing beliefs, barriers, and motivations. They come from HCP / patient behaviors and the way they seek and consume information, or from broader determinants like health equity, existing systems of care, or influence networks.

This vast, complex, ever-changing healthcare landscape can now be captured as data points and, thanks to advances in AI, can be analyzed and used to make smarter, faster decisions.

How Cognitev™ identifies high-value opportunities

Cognitev™, Inizio’s Commercial Intelligence Platform, combines this signal data, behavioral insights, and predictive modeling to identify:

The highest-value audiences by readiness and opportunity
The most relevant messages to different audiences
Which channels to target as the most likely to influence behavior
The most actionable moments as triggered when need, intent, or opportunity emerge

“If forecasting tells us where to play, then signals tell us where to win,” adds Will. “Success now belongs to those whose roadmap is not static, but adaptable. A signals-led launch system learns and continuously improves from pre-launch through to post-launch.”

3. Executing the plan: How do you mobilize and get ahead of challenges?

Accelerating commercial launch planning

Once you know what you need to do and where you need to do it, the next phase is being able to build and execute a robust launch plan.

LaunchNav, part of our Navigator AI™ platform, enables rapid development of a cross-functional launch plan, capturing detailed activities and benchmarked timing so it’s clear what needs to happen and when. And we can account for the foresight and signals information previously mentioned to ensure timely execution and aligned teams.

“Historically, it took eight to 10 weeks to capture all the cross-functional activities required for launch – now we’re able to do it in four to six weeks with LaunchNav,” says Ashley Stanley, Managing Director, Product Launch at Inizio Ignite. “Our launch plans are built on industry benchmarks and best practice, then tailored to a client’s unique launch needs.

“Many factors can affect a launch – LaunchNav uses detailed scenario-planning models to evaluate potential impacts and obstacles. By evaluating these scenarios, we can put mitigation plans in place so teams can react quickly if and when those challenges appear.”

Stress-testing pharma launch readiness

LaunchNav also allows clients to stress-test their launch plans at any time, identifying what’s working well or areas where the plan can be strengthened, enabling continuous refinement.

“For example, we recently used LaunchNav with a top five pharma company that had an early launch plan in place,” says Ashley. “They were looking for an objective sense-check on how ready they were. In just four weeks, we assessed their plan and identified multiple medium to high-priority risks, including more than 20 actions to take immediately to reduce those risks, cut costs, and focus their team on the issues that mattered most. We also identified several potential scenarios they’d overlooked, which they could be ready for.”

Bringing it all together for pharma launch success

For companies preparing to launch, the landscape and challenges are undoubtedly more complex than ever, but that doesn’t mean they have to do more – it means they have to act smarter, faster, and with greater precision.

Detailed forecasting aligned to dynamic segmentation will help you understand who you need to target and when. Signals-based targeting gives you an ever-changing view of the opportunities out there, allowing you to invest wisely and respond quickly. And benchmark-driven planning and scenario modeling will help your teams coordinate activities, identify priorities, mitigate risk, and move with greater confidence.

Bring all of this together and you give your product the highest possible chance of a successful launch.

Plan for pharma launch success with Inizio

Ready to improve your next pharmaceutical launch? Speak with our experts to see how Intelligent Commercialization™ can help reduce launch risk and accelerate launch readiness.